Arbutus Biopharma presented new clinical trial data for its two hepatitis B virus (HBV) assets, imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025. A late-breaker poster from the IM-PROVE II Phase 2a trial showed that imdusiran, combined with VTP-300 and low-dose nivolumab, led to a 25% functional cure rate in patients with baseline HBsAg levels less than 1000 IU/mL in the nivolumab-containing cohort.
Data from the Phase 1a/1b clinical trial for AB-101, an oral PD-L1 inhibitor, indicated that the 10mg dose administered once daily for 28 days was well-tolerated in chronic HBV patients. The trial also showed PD-L1 receptor occupancy similar to that observed in healthy volunteers, with no immune-related adverse events or evidence of liver dysfunction reported.
Across all Phase 2a clinical trials (IM-PROVE I and IM-PROVE II) conducted with imdusiran to date, Arbutus has reported a total of eight patients who have achieved a functional cure. These results reinforce the potential of Arbutus's combination therapy approach for cHBV.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.